Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 283

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Furosemide Stress Test and Biomarkers for the Prediction of AKI Severity

Open access
Koyner, Jay L., Davison, Danielle L., Brasha-Mitchell, Ermira, Chalikonda, Divya M., Arthur, John M., Shaw, Andrew D., Tumlin, James A., Trevino, Sharon A., Bennett, Michael R., Kimmel, Paul L., Seneff, Michael G., Chawla, Lakhmir S. · 2015 · Journal of the American Society of Nephrology

Abstract

Clinicians have access to limited tools that predict which patients with early AKI will progress to more severe stages. In early AKI, urine output after a furosemide stress test (FST), which involves intravenous administration of furosemide (1.0 or 1.5 mg/kg), can predict the development of stage 3 AKI. We measured several AKI biomarkers in our previously published cohort of 77 patients with early AKI who received an FST and evaluated the ability of FST urine output and biomarkers to predict the development of stage 3 AKI ( n =25 [32.5%]), receipt of RRT ( n =11 [14.2%]), or inpatient mortality ( n =16 [20.7%]). With an area under the curve (AUC)±SEM of 0.87±0.09 ( P <0.0001), 2-hour urine output after FST was significantly better than each urinary biomarker tested in predicting progression to stage 3 ( P <0.05). FST urine output was the only biomarker to significantly predict RRT (0.86±0.08; P =0.001). Regardless of the end point, combining FST urine output with individual biomarkers using logistic regression did not significantly improve risk stratification ( Δ AUC, P >0.10 for all). When FST urine output was assessed in patients with increased biomarker levels, the AUC for progression to stage 3 improved to 0.90±0.06 and the AUC for receipt of RRT improved to 0.91±0.08. Overall, in the setting of early AKI, FST urine output outperformed biochemical biomarkers for prediction of progressive AKI, need for RRT, and inpatient mortality. Using a FST in patients with increased biomarker levels improves risk stratification, although further research is needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2014060535

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 283

Metadata

Authors
Koyner, J. L., Davison, D. L., Brasha-Mitchell, E., Chalikonda, D. M., Arthur, J. M., Shaw, A. D., Tumlin, J. A., Trevino, S. A., Bennett, M. R., Kimmel, P. L., Seneff, M. G., & Chawla, L. S.
Venue
Journal of the American Society of Nephrology
Published
2015-08
Volume
26
Issue
8
Pages
2023-2031
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2165640077
Cited by
283
References
28
FWCI
23.20
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Furosemide Stress Test and Biomarkers for the Prediction of AKI Severity. https://app.cochat.ai/papers/10.1681/asn.2014060535
The paper
Koyner, J. L., Davison, D. L., Brasha-Mitchell, E., Chalikonda, D. M., Arthur, J. M., Shaw, A. D., Tumlin, J. A., Trevino, S. A., Bennett, M. R., Kimmel, P. L., Seneff, M. G., & Chawla, L. S. (2015). Furosemide Stress Test and Biomarkers for the Prediction of AKI Severity. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2014060535

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.